SNNA - Sienna Biopharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.00
+0.23 (+1.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.77
Open15.81
Bid0.00 x 800
Ask0.00 x 800
Day's Range15.66 - 16.23
52 Week Range12.77 - 26.00
Volume121,313
Avg. Volume70,153
Market Cap325.834M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-3.44
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.50
Trade prices are not sourced from all markets
  • GlobeNewswire25 days ago

    Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2

    Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a first-in-human study of its investigational new chemical entity SNA-125, a JAK3/TrkA inhibitor being evaluated as a first-in-class topically administered medication to treat mild-to-moderate psoriasis. SNA-125 was developed using Sienna’s Topical by Design™ platform, which yields new chemical entities (NCEs) designed to deliver high local drug concentration in the target tissue with minimal to no systemic exposure for patients. JAK3 inhibition blocks the signaling of key cytokines, resulting in reduced severity of certain autoimmune and inflammatory diseases such as psoriasis.

  • GlobeNewswirelast month

    Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results

    WESTLAKE VILLAGE, Calif., Aug. 09, 2018-- Sienna Biopharmaceuticals, Inc., a clinical-stage medical dermatology and aesthetics company, today reported the Company’ s financial results for the second quarter ...

  • GlobeNewswire2 months ago

    Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors

    Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that James (Jim) M. Hindman has been appointed to the Company’s Board of Directors. Mr. Hindman is the former chief financial officer and executive vice president, finance and business development of Allergan, Inc. and will join the Sienna Board of Directors immediately.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Social Reality Inc (NASDAQ: SRAX ) stock was trading ...

  • Reuters2 months ago

    Sienna Biopharmaceuticals' acne drug fails two trials

    Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its acne treatment did not meet their main goals of reducing inflammatory lesions on patients' skin. Sienna, which went public about ...

  • GlobeNewswire2 months ago

    Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints

    Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that two pivotal acne trials with SNA-001 in conjunction with 1064 nm and 810 nm lasers did not show statistical significance on the primary and secondary endpoints. SNA-001 is a topical medical product derived from Sienna’s proprietary Topical Photoparticle Therapy™ platform. Acne is a complex, multi-factorial disease affecting most people at some point in their lives," said Frederick C. Beddingfield III, MD, PhD, President and Chief Executive Officer of Sienna Biopharmaceuticals.

  • GlobeNewswire2 months ago

    Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis

    Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis. SNA-120 is a topical tropomyosin receptor kinase A (TrkA) inhibitor that blocks nerve growth factor (NGF) signaling, which plays an important role in the pathogenesis of itch and psoriasis. SNA-120 was developed using Sienna’s Topical by Design™ platform, which yields new chemical entities designed to deliver high local drug concentration in the target tissue and minimal to no systemic exposure for patients.

  • GlobeNewswire3 months ago

    Sienna Biopharmaceuticals Enters $40 Million Term Loan Agreement

    Sienna Biopharmaceuticals, Inc. (SNNA) today announced that the Company has entered a $40 million term loan agreement with Silicon Valley Bank. Sienna drew $30 million on closing. The remaining tranche of $10 million may be drawn at the Company’s discretion, subject to certain terms and conditions.

  • The 10 Best New Stocks of 2017
    InvestorPlace10 months ago

    The 10 Best New Stocks of 2017

    Too many of 2017’s initial public offerings, to be blunt, have been downright disasters. Snap Inc (NYSE:SNAP), the parent company of Snapchat, comes to mind. There’s also the not-so-small matter of Facebook Inc (NASDAQ:FB) more or less doing the same thing Snapchat does through its Instagram platform.